QIMR Berghofer Medical Research Institute
QIMR Berghofer Medical Research Institute is a world-leader in research into cancer, infectious diseases, mental health and chronic disorders. The Institute’s research spans prevention, early detection and effective treatment of some of the most deadly and difficult-to-treat diseases affecting Queenslanders and people throughout the world, especially those in tropical and equatorial regions in Asia and the Pacific, but also including Africa and the Americas.
Since its establishment in 1945, QIMR Berghofer has grown to become one of Australia’s largest, most successful and most respected medical research institutes. It is now home to around 900 scientists, students and support staff and boasts 65 state-of-the-art laboratories.
QIMR Berghofer’s cutting edge facilities include:
- Q-Pharm – a state-of-the-art early-phase clinical trial company that provides a broad range of high-quality services to commercial and academic clients around the world, specialising in early phase (Phases 1 and 2) clinical trials, bioequivalence, biosimilar, bioavailability and vaccine studies
- Q-Gen Cell Therapeutics – a fully integrated facility for translational research within QIMR Berghofer for manufacturing cell-based therapies and translating QIMR Berghofer’s clinical research to the bedside
- an insectary – the largest of its kind in the southern hemisphere and one of the largest in the world – to support research into mosquito control and mosquito-borne diseases
- integrated scientific services, including histology, flow cytometry, proteomics, sample processing, analytical services, DNA sequencing and genome informatics
QIMR Berghofer produces about 800 research papers a year, with more than 60 per cent having an international research collaborator named as an author. Recent research includes participation in a study led by researchers at the National Centre for Nanoscience and Technology in Beijing and the University of Chinese Academy of Sciences to design nanorobots made of DNA and protein that can be targeted directly at tumours to stop them growing. The Institute also hosts the Australian headquarters of the Beijing Genomics Institute.